The number of CD14+highCD16-, CD14+highCD16+ and CD14+lowCD16+ monocytes was prospectively investigated in patients with RA before initiation of anti-TNFα therapy and during the first six months of anti-TNFα treatment. Here, CD14 is linked to rheumatoid arthritis.